<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">P. Rousta</style></author><author><style face="normal" font="default" size="100%">Bruni, Laia</style></author><author><style face="normal" font="default" size="100%">Lina Schollin Ask</style></author><author><style face="normal" font="default" size="100%">Partha Basu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer</style></title><secondary-title><style face="normal" font="default" size="100%">JNCI: Journal of the National Cancer Institute</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">HPV</style></keyword><keyword><style  face="normal" font="default" size="100%">human papillomavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">patient data</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jul-03-2025</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong style=&quot;color:#69aa41;&quot;&gt;INTRODUCTION&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The Scottish study of Palmer et al., published in the current issue of this journal, linking vaccination files with cervical cancer screening data and the national cancer registry, demonstrates excellent protection against invasive cervical cancer among girls immunized at the age of 12 to 13 years with the bivalent human papillomavirus (HPV) vaccine (Cervarix, GSK, Rixensart, Belgium) (1). The study completes and strengthens the evidence of the&lt;br&gt;
high level of effectiveness of primary cervical cancer prevention by HPV vaccination based on intervention trials and populationbased surveillance of real-world data built up over the last two decades.&lt;/p&gt;
</style></abstract></record></records></xml>